Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2002

View Archived Issues

Postoperative CAT-152 superior to 5-FU in preventing scarring after glaucoma filtration surgery

Sustained transcleral delivery of EYE-001 achieved using PLGA microspheres

Development of etomoxir delayed; lower doses to be tested

VEGF receptor kinase inhibitor normalizes retinal vascular leakage in diabetic rats

New strategic focus announced by NeoTherapeutics

Squalamine reported to have beneficial effects in animal model of wet AMD

Ketoprofen amides with selective activity against COX-2

Second-generation ETA antagonist in clinical development for heart failure

BIRB-796BS: structure, pharmacological activity described at recent meeting

FDA approves Bravelle for infertility

NDA submission for palonosetron for chemotherapy-induced nausea and vomiting on track

Small-molecule RXR modulators useful for type 2 diabetes

CT-3 shows antispastic activity in animal model of MS

Periostat approved in Israel

Avalox i.v. cleared for market introduction in Germany

Cathepsin inhibitors and potential therapeutic uses described by Boehringer Ingelheim

Novuspharma and Cephalon collaborate on proteasome inhibition-based cancer therapies

DT031I identified as potential target in inflammatory diseases

PhotoCure presents update of progress in the first quarter

P&G patents series for use in the treatment of cancer or viral infections

Melanocortin receptor ligands synthesized at Procter & Gamble

Bayer patent discloses adenosine uptake inhibitors and uses thereof

Neurogen presents carboxamide ligands of the benzodiazepine site of GABA-A receptors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...